MAPT and Alzheimer disease: Tau oligomers have been detected in the brains of individuals with Alzheimer's disease (AD) and progressive supranuclear palsy, consistent with the view that nonfilamentous Tau aggregates may contribute to neurotoxicity (Castillo-Carranza et al., 2017).